The Journal of experimental medicine · 2026
Immune profiling links autoimmune hepatitis to human herpesvirus 6 and relaxin receptor antigens.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Klepper Arielle, Asaki James, Caspar Colette M, Kung Andrew F, Vazquez Sara E, Bodansky Aaron, Mitchell Anthea, Mann Sabrina A, Zorn Kelsey, Avila-Vargas Isaac, Kari Swathi, Tekeste Melawit, Castro Javier, Lee Briton, Duarte Maria, Khalili Mandana, Yang Monica, Wolters Paul, Price Jennifer, Perito Emily, Feng Sandy, Maher Jacquelyn J, Wilson Michael R, Lai Jennifer C, Weiler-Normann Christina, Lohse Ansgar W, DeRisi Joseph, Tana Michele May-Sien
Аннотация
Autoimmune hepatitis (AIH) is a severe, chronic disease where IgG elevation and autoantibody profile are defining features. However, linking autoantibodies to AIH pathogenesis remains elusive. We employed phage-display immunoprecipitation sequencing and uncovered a novel humoral signature specific to AIH. Embedded within this signature were antibodies against the known AIH autoantigen SLA/LP and novel reactivities to disco-interacting protein 2 homolog A (DIP2A), and the relaxin family peptide receptor 1 (RXFP1). Fine mapping of the DIP2A epitope revealed preferential enrichment for a nearly identical 9-amino acid sequence derived from the U27 protein of human herpesvirus 6 (HHV6). Preincubation with the HHV6 epitope blocked DIP2A binding, consistent with cross-reactivity. AIH patients positive for anti-DIP2A had higher titers of HHV6 IgG, suggestive of reactivation. AIH patients had antibodies against the antifibrotic receptor, RXFP1, which inhibited relaxin-2 signaling in an IgG-dependent manner. These data provide evidence for a novel serological profile in AIH, linking HHV6 reactivation anti-RXFP1 antibodies to disease pathogenesis.